Inhibitory effects of SR141716A on G-protein activation in rat brain.
about
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptorsHypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.Statistical parametric mapping reveals regional alterations in cannabinoid CB1 receptor distribution and G-protein activation in the 3D reconstructed epileptic rat brain.Are CB(1) Receptor Antagonists Nootropic or Cognitive Impairing Agents?Diuretic effects of cannabinoids.Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.Efficacy in CB1 receptor-mediated signal transductionEndocannabinoid tone versus constitutive activity of cannabinoid receptors.Cannabinoid receptor-interacting protein 1a modulates CB1 receptor signaling and regulationOpposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiationRimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trialStructural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptorsCB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression.Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specificEndocannabinoid-mediated control of synaptic transmission.The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogenCB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists.The vital role of constitutive GPCR activity in the mesolimbic dopamine system.Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist/Inverse Agonist AM251 on Sleep in Rats.Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity.Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
P2860
Q28185158-4C235A62-EBDC-4257-8EC0-9140150EE7F0Q28190374-18BA4860-C033-4163-986C-37F2CD17E34EQ30497569-3C400C88-FA1F-4E6A-B3FC-DB6F75D6AA46Q30551935-F6B47942-111A-4F87-ADAA-043928C3068DQ33901801-E9F4E575-0364-43A9-9222-E4D86303C92FQ34302379-AB3BA0AA-1868-4915-AECF-D0839A3068F2Q35047001-78C81A4E-62AD-4767-A35C-14A9AABCE708Q35047507-AAA1AA79-3EFC-438E-9F4B-C7F2B1A47728Q35193265-6B335315-D1EC-48D7-8B85-E7EFDE93DF65Q35198030-43AF9220-92A5-4175-9A9C-379DBAD2E636Q35688747-16941973-5FC4-4752-8884-D336819F266DQ35713057-24D36E77-BD22-4A2F-9B43-5C4A12F553BAQ35897867-A4CEBFFE-7674-4608-86CF-1055941AE32CQ36068400-93FD5FBE-001C-41D0-B5F4-12AD41BE2868Q36155353-5AE42C91-92BB-404E-B443-1B89F4761B27Q36712228-E4772231-B07B-4DBF-8B80-BA936D972F66Q36985211-A7771D17-CA0D-49A5-A9AE-EF5538C97885Q37031056-C66FD4FE-48F0-4CCA-9A5E-A43CE73953A4Q37089034-E1ED8FED-4EFB-4729-A484-31640D88A550Q37363621-F47DABF0-7A7F-4B6B-A9FD-3979A03DEEFDQ37416382-F1FB4490-99B5-4B35-A2AE-918EFD77520AQ37899264-BC825D90-78E5-4A0E-AA30-B337486B589BQ37984087-592FBCA3-02CB-4EE1-BB67-229097327F1EQ38187259-374E1439-CA7E-4BC6-9C82-1AFCFED52BDDQ38331225-A91A9B3A-1886-4BEE-B290-51026DF751CEQ40884726-80423FF7-C9B8-4A23-AD44-36CD8C9353E0Q41152430-57A9CE84-2F5E-4633-B42F-61C1D085D8C7Q41811457-471F0595-8C8C-4FAB-AC4B-42F161CEEF0AQ44046073-0812E31F-9798-426E-9B00-773BDE4E91C4Q44342705-BD5C5B47-9F54-473C-A772-DAD7FD85D4CAQ45153251-D0BA119C-FBAA-411B-9E0B-DAA63961CDEFQ45288843-B3A9613C-97AC-4F02-A3CE-EEAF491D17C7
P2860
Inhibitory effects of SR141716A on G-protein activation in rat brain.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@ast
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@en
type
label
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@ast
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@en
prefLabel
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@ast
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@en
P2093
P1476
Inhibitory effects of SR141716A on G-protein activation in rat brain.
@en
P2093
D E Selley
L J Sim-Selley
P304
P356
10.1016/S0014-2999(01)00784-1
P407
P577
2001-03-01T00:00:00Z